NCT01725269终止2 期
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 17
- 试验地点
- 25
- 主要终点
- To evaluate the intermediate/long-term safety of inhaled nebulized AIR001
研究概览
简要总结
The AIR001-CS05 study evaluated the safety and efficacy (effectiveness) of AIR001 over 16 weeks in subjects who have PAH. The purpose of the AIR001-CS06 study is to evaluate the intermediate / long-term safety of AIR001 in subjects who have completed the AIR001-CS05 study. Assessments to evaluate the effectiveness of the study drug will include measurements of exercise ability and evaluations of PAH disease symptoms.
详细描述
The primary objective of this study is to evaluate the intermediate/long-term safety of inhaled nebulized AIR001 administered according to 3 treatment arms (80 milligrams (mg) 4 times daily, 46 mg 4 times daily, or 80 mg once daily) in subjects with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH) who have completed the 16-week AIR001-CS05 study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study prior to initiation of any subject-mandated procedures.
- •Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •Has completed the 16-week AIR001-CS05study as planned.
- •If on corticosteroids, has been receiving a stable dose of less than or equal to 20 mg/day of prednisone (or equivalent dose, if other corticosteroid) for at least 1 month (30 days) prior to the AIR001-CS05 study Baseline/Day 1 visit. If receiving treatment for Connective Tissue Disease (CTD) with any other drugs, doses should remain stable, if clinically feasible, for the duration of the AIR001-CS06 study.
- •Women of childbearing potential must be using at least one form of medically acceptable contraception (i.e. either oral, topical, implanted hormonal contraceptives, or an intrauterine device) or two barrier methods; have a negative pregnancy test at Screening and Baseline/Day 1 and agree to use reliable methods of contraception until at least 24-hours after the last dose of study drug. Women who are surgically sterile (i.e. hysterectomy, bilateral oophorectomy, or tubal ligation) or those who are post-menopausal for at least 2 years are not considered to be of childbearing potential. Men who are not sterile (i.e. have not had a vasectomy) must also agree to use contraception until at least 24-hours after the last dose of study drug.
排除标准
- •Participation in a device or other interventional clinical studies (other than AIR001-CS05), within 1 month (30 days) of Baseline/Day 1 and/or during study participation.
- •Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure > 160 mmHg or sitting diastolic blood pressure > 100 mmHg during Baseline/Day 1 visit.
- •Systolic blood pressure < 90 mmHg at Baseline/Day
- •Diagnosis of Down syndrome.
- •Moderate to severe hepatic impairment classified as a Child-Pugh Class B or C at Baseline/Day
- •Has chronic renal insufficiency as defined by serum creatinine > 2.5 mg/dL or has an estimated Glomerular Filtration Rate (eGFR) < 30 mL/min at Baseline/Day 1, or requires dialytic support.
- •Has a hemoglobin (Hgb) concentration < 8.5 g/dL at Baseline/Day
- •Personal or family history of the following:
- •Congenital or acquired methemoglobinemia;
- •RBC CYPB5 reductase deficiency.
- •History of glucose-6-phosphate dehydrogenase (G6PD) deficiency or any contraindication to receiving methylene blue.
- •For subjects with Human immunodeficiency virus (HIV) associated PAH, requirement for the use of inhaled pentamidine.
- •The use of oral or topical nitrates (nitroglycerin, glyceryl trinitrate (GTN), isosorbide dinitrate, and isosorbide mononitrate) within 1 month (30 days) prior to Baseline/Day 1 or throughout the AIR001-CS06 study until EOS or Termination visit. Note: Intravenous GTN in an emergency setting may be administered by starting with a low dose and titrating upward, while the subject is being monitored closely for changes in blood pressure and heart rate.
- •Known or suspected hypersensitivity or allergic reaction to sodium nitrite or sodium nitrate.
- •History of malignancy within 5-years prior to Baseline/Day 1 of the AIR001-CS05 study, with the exception of localized non-metastatic basal cell carcinoma of the skin and in situ carcinoma of the cervix.
- •Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- •Has a psychiatric, addictive or other disorder that compromises the ability to give informed consent for participating in this study. This includes subjects with a recent history of abusing alcohol or illicit drugs 1 month (30 days) prior to study Baseline/Day 1 of the AIR001-CS05 study and for the duration of the study.
- •Is currently pregnant or breastfeeding or intends to become pregnant during the duration of the study.
- •Investigators, study staff or their immediate families.
研究组 & 干预措施
80mg AIR001, nebulized four times daily
Experimental
AIR001, 80 mg into nebulizer
干预措施: AIR001 (Drug)
46 mg AIR001, nebulized four times daily
Experimental
AIR001, 46 mg into nebulizer
干预措施: AIR001 (Drug)
80mg AIR001, nebulized once daily
Experimental
AIR001, 80 mg into nebulizer
干预措施: AIR001 (Drug)
结局指标
主要结局
To evaluate the intermediate/long-term safety of inhaled nebulized AIR001
时间窗: minimum of 6 months
The primary objective of this study is to evaluate the intermediate/long-term safety of inhaled nebulized AIR001 administered according to 3 treatment arms (80 milligrams (mg) 4 times daily, 46 mg 4 times daily, or 80 mg once daily) in subjects with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH) who have completed the 16-week AIR001-CS05 study.
次要结局
- To assess the effect of inhaled AIR001 on Time to Clinical Worsening, 6MWD, Functional Class, and Quality of Life(minimum of 6 months)
研究者
研究点 (25)
Loading locations...
相似试验
进行中（未招募）
2 期
Study of AZD2811 + Durvalumab in ES-SCLCSmall-Cell Lung CancerNCT04745689AstraZeneca31
Unknown
2 期
Study of HA121-28 in Patients With Non-Small Cell Lung CancerNSCLCNCT05117658CSPC ZhongQi Pharmaceutical Technology Co., Ltd.83
已完成
2 期
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic SyndromesHigh-risk Myelodysplastic SyndromeLow-risk Myelodysplastic SyndromeAcute Myeloid LeukemiaNCT03824080GWT-TUD GmbH45
终止
2 期
Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ AdenocarcinomaGastroesophageal Junction AdenocarcinomaGastric CancerNCT06206278LianBio LLC6
招募中
2 期
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasNeurofibromatosis 1Plexiform NeurofibromasNCT05331105Shanghai Kechow Pharma, Inc.70